2011 Annual Meeting | Frontiers in Movement Disorder Pharmacology
| 01:00 PM - 01:10 PM |
Introduction
John G. Nutt, MD, FAAN |
|
| 01:10 PM - 01:50 PM |
Pharmacological Approaches to Preventing Accumulation or Promoting Clearance of Abnormal Proteins in the CNS
C. W. Olanow, MD |
|
| 01:50 PM - 02:00 PM |
Questions and Answers
C. W. Olanow, MD |
|
| 02:00 PM - 02:40 PM |
Glutaminergic Neurotransmission: Multiple Opportunities for Therapeutic Intervention
Steven W. Johnson, MD, PhD |
|
| 02:40 PM - 02:50 PM |
Questions and Answers
Steven W. Johnson, MD, PhD |
|
| 02:50 PM - 03:05 PM |
Break
|
|
| 03:05 PM - 03:45 PM |
Subcortical Cholinergic Systems: Therapeutic Interventions for Gait and Balance
Nicolaas I. Bohnen, MD, PhD, FAAN |
|
| 03:45 PM - 03:55 PM |
Questions and Answers
Nicolaas I. Bohnen, MD, PhD, FAAN |
|
| 03:55 PM - 04:35 PM |
Networks and Systems Biology: Approaches to Identifying New Pharmacologic Targets
David Eidelberg, MD, FAAN, Andrew S. Feigin, MD |
|
| 04:35 PM - 04:45 PM |
Questions and Answers
David Eidelberg, MD, FAAN, Andrew S. Feigin, MD |
|
| 04:45 PM - 05:00 PM |
Discussion and Summary
John G. Nutt, MD, FAAN |
| John G. Nutt, MD, FAAN | No disclosure on file |
| C. W. Olanow, MD | Dr. Olanow has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Chevron/Syngenta. Dr. Olanow has stock in Clintrex Research Corporation. |
| Steven W. Johnson, MD, PhD | No disclosure on file |
| Nicolaas I. Bohnen, MD, PhD, FAAN | Dr. Bohnen has stock in Delta. The institution of Dr. Bohnen has received research support from NIH. The institution of Dr. Bohnen has received research support from VA. Dr. Bohnen has received research support from NIH. The institution of Dr. Bohnen has received research support from Parkinson fnd. |
| David Eidelberg, MD, FAAN | Dr. Eidelberg has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for MeiraGTx. Dr. Eidelberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TreeFrog Therapeutics. Dr. Eidelberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Blue Rock Therapeutics, Inc.. Dr. Eidelberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SANA Biotechnology, Inc. Dr. Eidelberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bio Vie, Inc.. Dr. Eidelberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for KenaiTx, Inc.. Dr. Eidelberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aspen Neuroscience. Dr. Eidelberg has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Oxford University Press. The institution of Dr. Eidelberg has received research support from The Michael J. Fox Foundation for Parkinson's Research. The institution of Dr. Eidelberg has received research support from Lupus Research Alliance. The institution of Dr. Eidelberg has received research support from National Institutes of Health. The institution of Dr. Eidelberg has received research support from Blue Rock Therapeutics. The institution of Dr. Eidelberg has received research support from National Institute of Neurological Disorders and Stroke. The institution of Dr. Eidelberg has received research support from The Michael J. Fox Foundation for Parkinson's Research. The institution of Dr. Eidelberg has received research support from National Institute of Allergy and Infectious Diseases. The institution of Dr. Eidelberg has received research support from Aspen Neurosciences, Inc. . The institution of Dr. Eidelberg has received research support from NIH. Dr. Eidelberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Eidelberg has received intellectual property interests from a discovery or technology relating to health care. |
| Andrew S. Feigin, MD | Dr. Feigin has received personal compensation for serving as an employee of Rho, Inc.. Dr. Feigin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kenai. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ADCS/ATRI. Dr. Feigin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Feigin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Feigin has received research support from Huntngton Study Group. The institution of Dr. Feigin has received research support from Prilenia. |